Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

References

• Adams J., Palombella V. J., Sausville E. A., Johnson J., Destree A., Lazarus D. D., Maas J., Pien C. S., Prakash S., Elliott P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 2615–2622, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bold R. J., Virudachalam S., McConkey D. J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 2001; 100: 11–17, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cusack J. C., Jr., Liu R., Houston M., Abendroth K., Elliott P. J., Adams J., Baldwin A. S., Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001; 61: 3535–3540, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hideshima T., Richardson P., Chauhan D., Palombella V. J., Elliott P. J., Adams J., Anderson K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 3071306–3071307
   Google Scholar
• Shah S. A., Potter M. W., McDade T. P., Ricciardi R., Perugini R. A., Elliott P. J., Adams J., Callery M. P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. 2001; 82: 110–122, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Logothetis C. J., Yang H., Daliani D., Millikan R. E., Tu S., Pagliaro L., Adams J., Elliott P., Nix D., Dieringer P., Papandreou C. N. Dose-dependent inhibition of 20S proteasome results in serum Il-6 and PSA decline in patients (pts) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc. Am. Soc. Clin. Oncol. 2001; 20: 186a
   Google Scholar
• Groll M., Ditzel L., Lowe J., Stock D., Bochtler M., Bartunik H. D., Huber R. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 1997; 386: 463–471, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lowe J., Stock D., Jap B., Zwickl P., Baumeister W., Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science 1995; 268: 53353–53359
   Google Scholar
• Stock D., Ditzel L., Baumeister W., Huber R., Lowe J. Catalytic mechanism of the 20S proteasome of thermoplasma acidophilum revealed by x-ray crystallography. Cold Spring Harbor Symp. Quant. Biol. 1995; 60: 525–532, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Nussbaum A. K., Dick T. P., Keilholz W., Schirle M., Stevanovic S., Dietz K., Heinemeyer W., Groll M., Wolf D. H., Huber R., Rammensee H. G., Schild H. Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 12504–12509, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9–16, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adams J., Behnke M., Chen S., Cruickshank A. A., Dick L. R., Grenier L., Klunder J. M., Ma Y. T., Plamondon L., Stein R. L. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 1998; 8: 33333–33338
   Google Scholar
• Dietrich C., Bartsch T., Schanz F., Oesch F., Wieser R. J. p53-Dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L- leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 10815–10819, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• An W. G., Hwang S. G., Trepel J. B., Blagosklonny M. V. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14: 1276–1283, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wu Y., Luo H., Kanaan N., Wu J. The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J. Cell. Biochem. 2000; 76: 596–604, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dulic V., Kaufmann W. K., Wilson S. J., Tlsty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013–1023, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• King R. W., Deshaies R. J., Peters J. M., Kirschner M. W. How proteolysis drives the cell cycle. Science 1996; 274: 1652–1659, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pagano M., Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., Yew P. R., Draetta G. F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682–685, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Desai S. D., Liu L. F., Vazquez-Abad D., D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J. Biol. Chem. 1997; 272: 24159–24164, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ogiso Y., Tomida A., Lei S., Omura S., Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 2000; 60: 2429–2434, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Adams J., Palombella V. J., Elliott P. J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 2000; 18(2)109–121, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Drexler H. C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 855–860, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Masdehors P., Omura S., Merle-Beral H., Mentz F., Cosset J. M., Dumont J., Magdelenat H., Delic J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 1999; 105: 752–757, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• An B., Goldfarb R. H., Siman R., Dou Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998; 5: 1062–1075, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kordes U., Krappmann D., Heissmeyer V., Ludwig W. D., Scheidereit C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399–402, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248–250, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Patel N. M., Nozaki S., Shortle N. H., Bhat-Nakshatri P., Newton T. R., Rice S., Gelfanov V., Boswell S. H., Goulet R. J., Jr., Sledge G. W., Jr., Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 1999; 19: 4159–4169, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Jeremias I., Kupatt C., Baumann B., Herr I., Wirth T., Debatin K. M. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624–4631, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baldwin A. S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 2001; 107: 241–246, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Scherer D. C., Brockman J. A., Chen Z., Maniatis T., Ballard D. W. Signal-induced degradation of IκBα requires site-specific ubiquitination. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 11259–11263, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Spencer E., Jiang J., Chen Z. J. Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev. 1999; 13: 284–294, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Winston J. T., Strack P., Beer-Romero P., Chu C. Y., Elledge S. J., Harper J. W. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev. 1999; 13: 270–283, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Alkalay I., Yaron A., Hatzubai A., Orian A., Ciechanover A., Ben-Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 10599–10603, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Baldi L., Brown K., Franzoso G., Siebenlist U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin- mediated proteolysis of IκB-α. J. Biol. Chem. 1996; 271: 376–379, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen Z., Hagler J., Palombella V. J., Melandri F., Scherer D., Ballard D., Maniatis T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev. 1995; 9: 1586–1597, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lin Y. C., Brown K., Siebenlist U. Activation of NF-κB requires proteolysis of the inhibitor IκB-α: signal-induced phosphorylation of IκB-α alone does not release active NF-κB. Proc. Natl. Acad. Sci. U. S. A. 1995; 92: 526–552
   Google Scholar
• Roff M., Thompson J., Rodriguez M. S., Jacque J. M., Baleux F., Arenzana-Seisdedos F., Hay R. T. Role of IκBα ubiquitination in signal-induced activation of NFκB in vivo. J. Biol. Chem. 1996; 271: 7844–7850, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen C., Edelstein L. C., Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 2000; 20: 2687–2695, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wang C. Y., Mayo M. W., Korneluk R. G., Goeddel D. V., Baldwin A. S., Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c- IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680–1683, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wang C. Y., Guttridge D. C., Mayo M. W., Baldwin A. S., Jr. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 1999; 19: 5923–5929, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Zong W. X., Edelstein L. C., Chen C., Bash J., Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 1999; 13: 382–387, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Russo S. M., Tepper J. E., Baldwin A. S., Jr., Liu R., Adams J., Elliott P., Cusack J. C., Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 183–193, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• LeBlanc R., Catley L., Hideshima T., Pien C. S., Elliott P. J., Anderson K. C. Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. Blood 2001; 98(11)
   Web of Science ®Google Scholar
• Pham L., Tamayo A., Lo P., Yoshimura L., Ford R. J. Antitumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001; 98(11)
   Web of Science ®Google Scholar
• Ma M. H., Parker K. M., Manyak S., Altamirano C. V., Wu Z. Q., Borad M. J., Roussos E., Neeser J., Mikail A., Frantzen M., Adams J., Yang H., Sjak-Shie N., Vescio R. A., Berenson J. R. Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. Blood 2001; 98(11)
   Web of Science ®Google Scholar
• Feinman R., Aris V. M., Vergano S., Galante A. T., Soteropoulos P., Gangurde P., Siegel D. S., Adams J., Elliott P. J., Tolias P. P. Transcriptional gene expression profiles in drug-sensitive and Bcl-2-resistant myeloma cells in response to dexamethasone arsenic trioxide, and PS-341. Blood 2001; 98(11)
   Web of Science ®Google Scholar
• Steiner P., Neumeier H., Lightcap E., Sadis S., Pien C., Pink M., Lesoon A., Rolfe M., Elliott P., Adams J., Bolen J., Read M. Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. Blood 2001; 98(11)
   Web of Science ®Google Scholar
• Nix D., Pien C., Newman R., Madden T., Felix E., Adams J., Elliott P. Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. Proc. Am. Soc. Clin. Oncol. 2001; 20: 86a
   Google Scholar
• Lightcap E. S., McCormack T. A., Pien C. S., Chau V., Adams J., Elliott P. J. Proteasome inhibition measurements: clinical application. Clin. Chem. 2000; 46: 673–683, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adams J. Proteasome inhibition in cancer: development of PS-341. Sem. Oncol. 2001; 28(6)613–619, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Papandreou C., Daliani D., Millikan R. E., Tu S., Pagliaro L., Adams J., Elliott P., Nix D., Dieringer P., Thall P., Logothetis C. J. Phase I study of IV proteasome inhibitor PS-341 in patients (pts) with advanced malignancies. Proc. Am. Soc. Oncol. 2001; 20: 86a
   Google Scholar
• Richardson P., Berenson J., Irwin D., Jagannath S., Singhal S., Traynor A., Rajkumar V., Alsina M., Kuter D., Srkalovic G., Siegel D., Barlogie B., Alexanian R., Orlowski R., Esseltine D., Kauffman M., Adams J., Schenkein D. P., Anderson K. C. Phase II study PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 2001; 98(11)
   Web of Science ®Google Scholar